Ardelyx Inc. Daily Stock Analysis

Daily Stock Analysis, ARDX, Ardelyx Inc, priceseries

Ardelyx Inc. Daily Stock Analysis
Stock Information
Open
0.92
Close
0.97
High
1.00
Low
0.88
Previous Close
0.92
Daily Price Gain
0.05
YTD High
1.20
YTD High Date
Jan 3, 2022
YTD Low
0.58
YTD Low Date
Feb 24, 2022
YTD Price Change
-0.21
YTD Gain
-17.81%
52 Week High
9.23
52 Week High Date
Apr 15, 2021
52 Week Low
0.58
52 Week Low Date
Feb 24, 2022
52 Week Price Change
-5.29
52 Week Gain
-84.51%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 19. 2017
4.65
Jul 6. 2017
5.10
12 Trading Days
9.78%
Link
LONG
Nov 16. 2017
5.60
Dec 4. 2017
6.06
11 Trading Days
8.15%
Link
LONG
Dec 19. 2017
6.35
Jan 8. 2018
6.87
12 Trading Days
8.20%
Link
LONG
Jan 4. 2019
2.06
Jan 16. 2019
2.25
8 Trading Days
9.23%
Link
LONG
Feb 6. 2019
2.26
Mar 26. 2019
3.18
33 Trading Days
40.88%
Link
LONG
Apr 4. 2019
3.07
Apr 17. 2019
3.35
9 Trading Days
9.06%
Link
LONG
Aug 16. 2019
2.47
Aug 30. 2019
3.26
10 Trading Days
31.91%
Link
LONG
Nov 7. 2019
5.48
Dec 4. 2019
6.68
18 Trading Days
21.94%
Link
LONG
Apr 8. 2020
5.71
Apr 30. 2020
6.86
15 Trading Days
20.11%
Link
LONG
Mar 31. 2021
6.62
Apr 12. 2021
7.02
7 Trading Days
6.05%
Link
LONG
Nov 30. 2021
1.14
Dec 13. 2021
1.39
9 Trading Days
21.74%
Link
Company Information
Stock Symbol
ARDX
Exchange
NasdaqGM
Company URL
http://www.ardelyx.com
Company Phone
510-745-7047
CEO
Michael G. Raab
Headquarters
California
Business Address
34175 ARDENWOOD BLVD., FREMONT, CA 94555
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001437402
About

Ardelyx, Inc. operates as a clinical-stage biopharmaceutical company that engages in the discovery, development, and commercialization of minimally-systemic, small molecule therapeutics that work exclusively in the gastrointestinal, tract to treat gastrointestinal and cardio-renal diseases. The company's products include Tenapanor, RDX002, RDX009 and RDX013. Ardelyx was founded by Dominique Charmot, Peter G. Schultz and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.

Description

Ardelyx, Inc. develops and sells therapeutics for the treatment of cardio renal and gastrointestinal diseases in the United States. Its lead product candidate is tenapanor, which is in Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. The company is also developing RDX7675, which is in Phase III clinical trial for the treatment of people with hyperkalemia; and RDX8940 in Phase I clinical trial for the treatment of patients with NASH and other gastrointestinal indications. Its drug candidates in the stages of research and development include RDX013 for the treatment of patients with hyperkalemia; RDX011 for the discovery and development of second-generation NHE3 inhibitors; and RDX023 for the discovery and development of gut-biased FXR agonists for the treatment of GI and inflammatory diseases. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading